Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMGN151 + olaparib
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
IMGN151 + olaparib is a combination therapy under clinical investigation for the treatment of gynecologic cancers, particularly ovarian and other related cancers. IMGN151 is an antibody-drug conjugate (ADC) designed to deliver a cytotoxic payload specifically to cancer cells expressing certain surface antigens, thereby minimizing off-target toxicity. Olaparib is a small-molecule inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, which impairs DNA repair in BRCA-mutated or homologous recombination-deficient cancer cells, leading to cancer cell death. The combination is being evaluated to assess synergistic antineoplastic activity and improved outcomes in gynecologic oncology, likely leveraging IMGN151’s targeted cytotoxicity and olaparib’s DNA repair inhibition[1][3][5].
- Brand names
- Lynparza
- Other names
- IMGN151 + olaparib
02
Targets
B7-H3PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on IMGN151 + olaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMGN151 + olaparib.